{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:05:50Z","timestamp":1758773150890,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.urology.2022.12.022","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T01:52:37Z","timestamp":1672451557000},"page":"5-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A Primer on the History of Intralesional Verapamil Injection for Peyronie's Disease"],"prefix":"10.1016","volume":"173","author":[{"given":"Laurence A.","family":"Levine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2022.12.022_bib0001","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/17512433.2021.1903873","article-title":"Peyronie's disease: pharmacological treatment's and limitations","volume":"14","author":"Li","year":"2021","journal-title":"Expert Rev Clin Pharm"},{"key":"10.1016\/j.urology.2022.12.022_bib0002","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1743-6109.2007.00674.x","article-title":"Urologist practice patterns in the management of Peyronie's disease: a nationwide survey","volume":"5","author":"Shindel","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2022.12.022_bib0003","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.sxmr.2019.12.002","article-title":"Noninvassive treatment options for Peyronie's disease","volume":"8","author":"Ory","year":"2020","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.urology.2022.12.022_bib0004","doi-asserted-by":"crossref","unstructured":"Russo GI, Cacciamani G, Cocci A. Comparative effectiveness of intralesional therapy for Peyronie's disease in controlled clinical studies. J Sex Med. 2019;16:289\u2013299","DOI":"10.1016\/j.jsxm.2018.12.011"},{"key":"10.1016\/j.urology.2022.12.022_bib0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0022-4804(90)90197-A","article-title":"Calcium antagonists retard extracellular matrix production in connective tissue equivalent","volume":"49","author":"Lee","year":"1990","journal-title":"J Surg Res"},{"key":"10.1016\/j.urology.2022.12.022_bib0006","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1083\/jcb.98.5.1662","article-title":"Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts","volume":"98","author":"Aggeler","year":"1984","journal-title":"J Cell Biol"},{"key":"10.1016\/j.urology.2022.12.022_bib0007","doi-asserted-by":"crossref","unstructured":"Roth M, Eickelberg O, Kohler E. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci. 1996;28:5478\u20135482.","DOI":"10.1073\/pnas.93.11.5478"},{"key":"10.1016\/j.urology.2022.12.022_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(17)35291-6","article-title":"Intralesional verapamil injection for the treatment of Peyronie's disease","volume":"151","author":"Levine","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.12.022_bib0009","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0022-5347(01)64224-1","article-title":"Treatment of Peyronie's disease with intralesional verapamil injection","volume":"158","author":"Levine","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.12.022_bib0010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","article-title":"Experience with intraplaque injection of verapamil for Peyronie's diesease","volume":"168","author":"Levine","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2022.12.022_bib0011","first-page":"269","article-title":"Clinical effects of verapamil in the treatment of Peyronie's disease","volume":"66","author":"Arena","year":"1995","journal-title":"Acta Biomed Ateneo Parmense"},{"key":"10.1016\/j.urology.2022.12.022_bib0012","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.urology.2007.02.042","article-title":"Intralesional verapamil prevents the progression of Peyronie's disease","volume":"69","author":"Bennett","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2022.12.022_bib0013","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","article-title":"Combination pf penile traction, intalesional verapamil, and oral therapies for Peyronie's disease","volume":"9","author":"Abern","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2022.12.022_bib0014","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of Peyronie's disease with PDE5 inhibitors: an antibiotic strategy","volume":"7","author":"Gonzalez-Cadavid","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urology.2022.12.022_bib0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","article-title":"Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease","volume":"97","author":"Ferini","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2022.12.022_bib0016","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JU.0000000000000245","article-title":"Outcomes of a novel penile traction device in men with Peyronie's disease: a randomized, single-blind controlled trial","volume":"202","author":"Zigelmann","year":"2019","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522010974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429522010974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:00:10Z","timestamp":1758769210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429522010974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":16,"alternative-id":["S0090429522010974"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2022.12.022","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Primer on the History of Intralesional Verapamil Injection for Peyronie's Disease","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2022.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}